Pembrolizumab

The FDA approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer, according to an agency press release.

Pembrolizumab plus olaparib did not improve outcomes among patients with locally recurrent inoperable or metastatic triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — An immunotherapy-chemotherapy combination conferred benefit for certain patients with high-risk breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Treatment with selpercatinib for advanced RET fusion-positive non-small cell lung cancer resulted in significantly longer PFS compared with platinum-based chemotherapy with or without pembrolizumab, study results showed.

A recent analysis of global conversations involving almost 1,500 health care professionals on social media from Oct. 1 to 31 has revealed a predominantly positive reaction to the FDA’s approval of Novavax’s updated COVID-19 vaccine.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

The FDA approved pembrolizumab for use with chemotherapy to treat HER2-negative gastric or gastroesophageal junction adenocarcinoma.

NASHVILLE, Tenn. — Adjuvant pembrolizumab appeared well tolerated among patients with high-risk renal cell carcinoma after nephrectomy, according to study results.

The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.